Sebela Women's Health Announces Further Positive Data from the Pivotal Phase 3 Study of the Investigational Copper 175 mm² Intra-Uterine Device (IUD)

/PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced additional positive data from the pivotal Phase 3 open-label...

Related Keywords

Dublin ,Ireland ,San Diego ,California ,United States ,American ,Kelly Culwell ,Jacquelyne Froeber ,Davidk Turok ,David Turok ,Danita Nelson ,Sebela Women Health Inc ,University Of Utah ,Division Of Family Planning ,Prnewswire Sebela Women Health Inc ,Head Of Research ,Braintree Laboratories Inc ,Scientific Congress ,Sebela Women Health ,American Society Of Reproductive Medicine ,American College Of Obstetrics ,Sebela Pharmaceuticals ,Nurse Practitioners In Women Health ,Access Health ,Committee Statement ,Sebela Pharmaceuticals Inc ,Drug Administration ,Department Of Obstetrics ,Society Of Family Planning ,Health Inc ,Sebela Women ,Investigational Copper ,American College ,Principal Investigator David ,Associate Professor ,Pain Dramatically Decreased After First Three ,Family Planning ,Annual Meeting ,Novel Low Dose Copper Intrauterine Contraceptive ,Flexible Nitinol Frame ,Clinical Trials ,Encore Data ,Essential Access Health ,Pearl Index ,Good Clinical Practice ,Pelvic Infection Low Regardless ,Past Medical History ,Neisseria Gonorrhoeae ,Reproductive Medicine ,New Orleans ,Private Securities Litigation Reform Act ,Taking Control ,More Communication About ,Issued May ,Clinical Practice Bulletin ,Englj Med ,